NEWS
Mastercard launches Biometric Checkout Program in Uruguay
Mastercard has announced the expansion of its global Biometric Checkout Program in Latin America .
With partners Ingenico , Fulcrum Biometrics , Fujitsu Frontech and Scanntech , Mastercard has launched an innovative in-store biometric payment experience at Tienda Inglesa ’ s Red Expres in Uruguay .
This is the first Biometric Checkout Program pilot that allows registered shoppers to pay with their palm and the second pilot in the LATAM region .
“ We are excited to expand our Biometric Checkout Program further into Latin America with the launch of our pilot program at Red Expres ,” said Federico Cofman , Cluster Lead for Argentina , Paraguay and Uruguay , Mastercard .
The cutting-edge payment system , developed by Ingenico and Fulcrum Biometrics , a Fujitsu company , enables pilot participants to register their palm biometrics and link it to any debit , prepaid or credit card – allowing them to seamlessly pay without a wallet or device .
Launched in Spring 2022 in Brazil , Mastercard ’ s Biometric Checkout Program announced an expansion of the program to the APAC region last year .
To continue to advance in-store biometrics , Mastercard will launch several biometric pilots later this year in countries across the globe .
“ Consumers are looking for more choice in how they pay and thanks to our collaborative innovation , we can deliver more seamless , secure payment experiences .”
Mastercard ’ s Biometric Checkout Program represents a first-of-itskind technology framework to establish standards for new ways to pay in-store .
Massive Bio and UEPM partner to transform oncology clinical trial access and deploy AI technologies across LATAM
UEPM , a premier clinical trial search platform in Latin America and Massive Bio , a leader in AI-driven oncology solutions , have announced an expanded partnership .
The collaboration will extend Massive Bio ’ s reach across nine LATAM countries , including Mexico , Colombia , Brazil and Argentina , to improve clinical trial access and patient care .
Dr Selin Kurnaz PhD , Co-Founder and CEO , Massive Bio , said : “ By leveraging UEPM ’ s extensive network and our AI technology , we can ensure that more patients in LATAM have access to cuttingedge therapies .”
Massive Bio ’ s advanced AI technology streamlines the clinical trial enrolment process , reducing the time and effort required for patient matching . This partnership will facilitate better access to clinical trials for cancer patients in LATAM , helping to bridge the gap between innovative treatments and the patients who need them most .
Dr Georgina Sposetti , CEO and Founder , UEPM , said : “ This collaboration will significantly improve the accessibility and efficiency of finding suitable clinical trials for our cancer patients , ultimately enhancing their treatment outcomes and quality of life .”
The UEPM platform allows patients and healthcare providers to search for clinical trials that match specific medical conditions and treatment needs .
By integrating Massive Bio ’ s AI-driven solutions , UEPM can offer more accurate and timely clinical trial matches – increasing participation rates and advancing cancer research .
www . intelligentcio . com INTELLIGENTCIO LATAM 9